The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS

References

• Garcia-Velasco JA, Pellicer A. New concepts in the understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 2003;15:251–56
   PubMed Web of Science ®Google Scholar
• Aboulghar M. Prediction of ovarian hyperstimulation syndrome (ohss). Estradiol level has an important role in the prediction of ohss. Hum Reprod 2003;18:1140–41
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (ohss). Hum Reprod Update 2003;9:77–96
   PubMed Web of Science ®Google Scholar
• Carizza C, Abdelmassih V, Abdelmassih S, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: A prospective randomized study. Reprod Biomed Online 2008;17:751–55
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (ohss): a review. Hum Reprod Update 2002;8:559–77
   PubMed Web of Science ®Google Scholar
• Mathur RS, Jenkins JM. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome? BJOG 2000;107:943–46
   PubMed Web of Science ®Google Scholar
• Aboulghar M. Symposium: update on prediction and management of ohss. Prevention of ohss. Reprod Biomed Online 2009;19:33–42
   PubMed Web of Science ®Google Scholar
• Papaleo E, Doldi N, De Santis L, et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod 2001;16:2263–66
   PubMed Web of Science ®Google Scholar
• Knoepfelmacher M, Danilovic DL, Rosa Nasser RH, Mendonca BB. Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. Fertil Steril 2006;86:719 e715–18
   Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (vegf)-mediated vascular hyperpermeability without altering vegf receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400–11
   PubMed Web of Science ®Google Scholar
• Alvarez C, Alonso-Muriel I, Garcia G, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: A pilot study. Hum Reprod 2007;22:3210–14
   PubMed Web of Science ®Google Scholar
• Zachow R, Uzumcu M. The hepatocyte growth factor system as a regulator of female and male gonadal function. J Endocrinol 2007;195:359–71
   PubMed Web of Science ®Google Scholar
• Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629–41
   PubMed Web of Science ®Google Scholar
• Parrott JA, Skinner MK. Developmental and hormonal regulation of hepatocyte growth factor expression and action in the bovine ovarian follicle. Biol Reprod 1998;59:553–60
   PubMed Web of Science ®Google Scholar
• Parrott JA, Skinner MK. Thecal cell-granulosa cell interactions involve a positive feedback loop among keratinocyte growth factor, hepatocyte growth factor, and kit ligand during ovarian follicular development. Endocrinology 1998;139:2240–45
   PubMed Web of Science ®Google Scholar
• Choi YS, Ku SY, Jee BC, et al. Comparison of follicular fluid igf-i, igf-ii, igfbp-3, igfbp-4 and papp-a concentrations and their ratios between gnrh agonist and gnrh antagonist protocols for controlled ovarian stimulation in ivf-embryo transfer patients. Hum Reprod 2006;21:2015–21
   PubMed Web of Science ®Google Scholar
• Wang TH, Chang CL, Wu HM, et al. Insulin-like growth factor-ii (igf-ii), igf-binding protein-3 (igfbp-3), and igfbp-4 in follicular fluid are associated with oocyte maturation and embryo development. Fertil Steril 2006;86:1392–401
   PubMed Web of Science ®Google Scholar
• Moos J, Rezabek K, Filova V, et al. Comparison of follicular fluid and serum levels of inhibin a and inhibin b with calculated indices used as predictive markers of ovarian hyperstimulation syndrome in ivf patients. Reprod Biol Endocrinol 2009;7:86--93
   PubMed Web of Science ®Google Scholar
• Lee JR, Kim SH, Kim SM, et al. Follicular fluid anti-mullerian hormone and inhibin b concentrations: Comparison between gonadotropin-releasing hormone (gnrh) agonist and gnrh antagonist cycles. Fertil Steril 2008;89:860–67
   PubMed Web of Science ®Google Scholar
• Seifer DB, MacLaughlin DT, Penzias AS, et al. Gonadotropin-releasing hormone agonist-induced differences in granulosa cel cycle kinetics are associated with alterations in follicular fluid mullerian-inhibiting substance and androgen content. J Clin Endocrinol Metab 1993;76:711–14
   PubMed Web of Science ®Google Scholar
• Silberstein T, MacLaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of hcg administration in ivf cycles predict both ovarian reserve and embryo morphology. Hum Reprod 2006;21:159–63
   PubMed Web of Science ®Google Scholar
• Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21:2022–26
   PubMed Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (pcos). Hum Reprod 2004;19:41–47
   Google Scholar
• Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: Guidance for the clinician. Fertil Steril 2010;94:389–400
   PubMed Web of Science ®Google Scholar
• Ozdegirmenci O, Dilbaz S, Cinar O, et al. Can serum oestradiol be a predictor of quality of oocytes and embryos, maturation of oocytes and pregnancy rate in icsi cycles? Gynecol Endocrinol 2011;27:279–85
   PubMed Web of Science ®Google Scholar
• Baczkowski T, Kurzawa R, Glabowski W. Methods of embryo scoring in in vitro fertilization. Reprod Biol 2004;4:5–22
   PubMedGoogle Scholar
• Garcia-Velasco JA. How to avoid ovarian hyperstimulation syndrome: A new indication for dopamine agonists. Reprod Biomed Online 2009;18:71–75
   PubMed Web of Science ®Google Scholar
• Fried G, Remaeus K, Harlin J, et al. Inhibin b predicts oocyte number and the ratio igf-i/igfbp-1 may indicate oocyte quality during ovarian hyperstimulation for in vitro fertilization. J Assist Reprod Genet 2003;20:167–76
   PubMed Web of Science ®Google Scholar
• Penarrubia J, Fabregues F, Manau D, et al. Basal and stimulation day 5 anti-mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment. Hum Reprod 2005;20:915–22
   PubMed Web of Science ®Google Scholar
• Laven JS, Mulders AG, Visser JA, et al. Anti-mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318–23
   PubMed Web of Science ®Google Scholar
• Josso N, Racine C, di Clemente N, et al. The role of anti-mullerian hormone in gonadal development. Mol Cell Endocrinol 1998;145:3–7
   PubMed Web of Science ®Google Scholar
• Chang CL, Wang TH, Horng SG, et al. The concentration of inhibin b in follicular fluid: Relation to oocyte maturation and embryo development. Hum Reprod 2002;17:1724–28
   PubMed Web of Science ®Google Scholar
• Ocal P, Aydin S, Cepni I, et al. Follicular fluid concentrations of vascular endothelial growth factor, inhibin a and inhibin b in ivf cycles: are they markers for ovarian response and pregnancy outcome? Eur J Obstet Gynecol Reprod Biol 2004;115:194–99
   PubMed Web of Science ®Google Scholar
• Enskog A, Nilsson L, Brannstrom M. Peripheral blood concentrations of inhibin b are elevated during gonadotrophin stimulation in patients who later develop ovarian ohss and inhibin a concentrations are elevated after ohss onset. Hum Reprod 2000;15:532–38
   PubMed Web of Science ®Google Scholar
• Skinner MK. Regulation of primordial follicle assembly and development. Hum Reprod Update 2005;11:461–71
   PubMed Web of Science ®Google Scholar
• Guglielmo MC, Ricci G, Catizone A, et al. The effect of hepatocyte growth factor on the initial stages of mouse follicle development. J Cell Physiol 2011;226:520–29
   PubMed Web of Science ®Google Scholar
• Dorn C, Reinsberg J, Kupka M, et al. Leptin, vegf, igf-1, and igfbp-3 concentrations in serum and follicular fluid of women undergoing in vitro fertilization. Arch Gynecol Obstet 2003;268:187–93
   PubMedGoogle Scholar
• Yoshimura Y. Insulin-like growth factors and ovarian physiology. J Obstet Gynaecol Res 1998;24:305–23
   PubMedGoogle Scholar
• Elias AN, Stone SC, Tayyanipour R, et al. Relationship between serum estradiol concentration and igf-i, igf-ii and igf-binding proteins in patients with premature ovarian failure on short-term estradiol therapy. Int J Fertil Menopausal Stud 1995;40:196–201
   PubMedGoogle Scholar
• Silva JR, Figueiredo JR, van den Hurk R. Involvement of growth hormone (gh) and insulin-like growth factor (igf) system in ovarian folliculogenesis. Theriogenology 2009;71:1193–208
   PubMed Web of Science ®Google Scholar
• Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 2003;42:633–45
   PubMed Web of Science ®Google Scholar